Literature DB >> 22902972

Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe.

Jan Bonhoeffer1, Steve Black, Hector Izurieta, Patrick Zuber, Miriam Sturkenboom.   

Abstract

Vaccine safety research is a key component of public health programs. Regulatory agencies need to be able to make informed decisions. Public health authorities need to respond to vaccine concerns before they turn into large scale scares reducing vaccine uptake and derailing immunization programs. Several post-licensure vaccine safety monitoring systems have been established in the USA and Europe, and methods such as rapid cycle analysis have been developed for real-time detection and analysis of safety issues. Accurate and reliable vaccine product testing and monitoring requires high quality data of populations of 100 million and above depending on the frequency of the event, vaccine coverage, and the time pressure during which data need to be generated. This requires post-licensure safety studies utilizing large linked population based databases of exposure and outcomes. Harmonized methods for development and linkage of these databases across countries need to be further developed, validated and implemented. Concerted action between the US and Europe could move vaccine safety monitoring to today's level of requirements globally and should be pursued. Published by Elsevier Ltd.

Mesh:

Substances:

Year:  2012        PMID: 22902972     DOI: 10.1016/j.biologicals.2012.07.007

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  9 in total

Review 1.  Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): clues and pitfalls in the pediatric background.

Authors:  Susanna Esposito; Elisabetta Prada; Maria Vincenza Mastrolia; Giusyda Tarantino; Claudio Codecà; Donato Rigante
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.

Authors:  Hazel J Clothier; Nigel W Crawford; Melissa Russell; Heath Kelly; Jim P Buttery
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

Review 3.  Ontology-supported research on vaccine efficacy, safety and integrative biological networks.

Authors:  Yongqun He
Journal:  Expert Rev Vaccines       Date:  2014-06-07       Impact factor: 5.217

4.  Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.

Authors:  Cristiano Alicino; Caterina Merlano; Simona Zappettini; Sergio Schiaffino; Giovanni Della Luna; Cristina Accardo; Roberto Gasparini; Paolo Durando; Giancarlo Icardi
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 5.  Sustaining Vaccine Confidence in the 21st Century.

Authors:  Karin Hardt; Ruprecht Schmidt-Ott; Steffen Glismann; Richard A Adegbola; François P Meurice
Journal:  Vaccines (Basel)       Date:  2013-06-24

Review 6.  Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods.

Authors:  Andreia Leite; Nick J Andrews; Sara L Thomas
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-28       Impact factor: 2.890

7.  Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC).

Authors:  Hugo Arlegui; Kaatje Bollaerts; Vincent Bauchau; Gaëlle Nachbaur; Bernard Bégaud; Nicolas Praet
Journal:  Drug Saf       Date:  2020-11       Impact factor: 5.606

Review 8.  Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review.

Authors:  Hugo Arlegui; Gaëlle Nachbaur; Nicolas Praet; Bernard Bégaud
Journal:  Open Forum Infect Dis       Date:  2020-03-12       Impact factor: 3.835

Review 9.  Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.

Authors:  Hugo Arlegui; Kaatje Bollaerts; Francesco Salvo; Vincent Bauchau; Gaëlle Nachbaur; Bernard Bégaud; Nicolas Praet
Journal:  Drug Saf       Date:  2020-11       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.